ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,180.74
1.03%
US Tech 100
17,598.80
1.03%
다우존스 지수
38,852.27
0.46%
Bitcoin
63,529.96
0.58%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. EyePoint Pharmaceuticals Inc (EYPT)

  7. EyePoint Pharmaceuticals Inc (EYPT) 뉴스

EYPT

EyePoint Pharmaceuticals (EYPT)

EyePoint Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:EYPT
일자시간출처헤드라인심볼기업
2024/05/0622:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/05/0620:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic RetinopathyNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/04/1620:00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/04/0220:00GlobeNewswire Inc.EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina SpecialistsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/03/1820:00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/03/0903:53Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/03/0721:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/03/0721:00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate DevelopmentsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/03/0507:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/03/0507:37Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/03/0421:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/03/0421:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical OfficerNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/2921:00GlobeNewswire Inc.EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/2721:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Participation at Upcoming Investor ConferencesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/2307:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/1621:00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/1511:08Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/1407:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/1407:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/1407:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/1407:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/1407:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/1402:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/0607:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/0406:20GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular DegenerationNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/0306:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/01/3121:00GlobeNewswire Inc.EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/01/3106:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/01/3007:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/01/3007:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:EYPT

최근 히스토리

AMEX
XLE
Energy Select Sector SPDR
NASDAQ
NVDA
NVIDIA
NYSE
KO
Coca Cola
NASDAQ
TSLA
Tesla
NYSE
BAC
Bank of America
NASDAQ
AAPL
Apple
AMEX
SPY
SPDR S&P 500
USOTC
RHHBY
Roche (QX)
AMEX
XLV
Health Care Select Sector
NYSE
MRK
Merck
NYSE
MCD
McDonalds
SPI
SP500
S&P 500
USI
USTECH100
US Tech 100
FX
USDJPY
US Dollar vs Yen
COIN
SOLUSD
Solana
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유